ArticleBulletin of experimental biology and medicine2025
Analysis of Increased False-Positive ELISA Results for HIV in the Blood of Donors Infected with SARS-CoV-2.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study examined the effect of IgG antibodies against SARS-CoV-2 virus in the blood of donors after COVID-19 on objectivity of HIV detection in the blood samples with two ELISA variants employing reagents A or B in order to select reliable kits to minimize the false-positive HIV results. Retrospectively, the quality control data of two ELISA kits with reagents A or B developed to detect HIV were analyzed using the control sera together with the results of donor blood tested with both kits, which were collected in the periods from January to December 2022 (n = 55,528) and from January to March 2023 (n = 13,837). From the blood samples obtained in 2023, all the specimens with false-positive HIV results obtained with reagent A were selected (n = 126) together with randomly taken samples of this pool with negative HIV results (n = 345). All selected samples were tested for IgG antibodies against SARS-CoV-2 virus, thereupon the correlation analysis was performed between the samples containing SARS-CoV-2 and those with HIV detected by ELISA reagent A. The data on reactivity of IgG antibodies against SARS-CoV-2 significantly correlated with the false-positive ELISA results for HIV obtained with reagent A (r = 0.451, p < 0.01). In 2023, the share of false-positive ELISA results for HIV obtained with reagent A was 0.91% (126/13,837), which was 6.06-fold greater than the corresponding value in 2022 (0.133% (74/55,528); χ
Indexed as
Identifiers
40448880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.